MeSH D007951 - myeloid leukemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D007938:Leukemia
D007951:Â
Myeloid leukemia
D015464:Bcr-abl positive chronic myelogenous leukemia
D015470:Myeloid leukemia acute
D015477:Myelomonocytic leukemia chronic
D015479:Myelomonocytic leukemia acute
D023981:Myeloid sarcoma
0 Companies
0 Drugs
Success rate
D054429:Myelomonocytic leukemia juvenile
0 Companies
0 Drugs
Success rate
D054438:Leukemia myeloid chronic atypical bcr-abl negative
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Imatinib | Imatinib |  | 2016-08-04 |  |  |
| Imatinib | Imatinib Teva |  | 2013-01-07 |  |  | |
| Imatinib | Imatinib Teva B.V |  | 2017-11-15 |  |  | |
| Mylan | Imatinib | Imatinib |  | 2017-06-21 |  |  |
| Johnson & Johnson | Decitabine | Dacogen |  | 2012-09-20 |  |  |
| Novartis | Imatinib | Gleevec |  | 2001-05-10 | $887 M | Q2/20-Q2/23 |
| Imatinib | Glivec |  | 2001-11-07 |  |  | |
| Asciminib | Scemblix | 2033-05-13 | 2021-10-29 | $137 M | Q2/22-Q2/23 | |
| Pfizer | Bosutinib | Bosulif |  | 2013-03-27 | $645 M | Y2023 |
| Takeda | Ponatinib | Iclusig | 2026-12-22 | 2012-12-14 |  |  |
| Dr Reddys Laboratories | Imatinib | Imatinib |  | 2018-08-13 |  |  |
| Zydus Therapeutics | Imatinib | Imatinib |  | 2020-04-08 |  |  |
| Sun Pharmaceutical Industries | Imatinib | Imatinib |  | 2015-12-03 |  |  |
| Apotex | Dasatinib | Dasatinib |  | 2016-06-10 |  |  |
| Imatinib | Imatinib |  | 2016-08-05 |  |  | |
| Ponatinib | Ponatinib |  | 2023-07-14 |  |  |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
60%32/53
Phase 2
44%27/62
Phase 3
24%9/37
Approved: 7Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use